Down-regulated surfactant protein B in obese asthmatics

Clin Exp Allergy. 2022 Nov;52(11):1321-1329. doi: 10.1111/cea.14124. Epub 2022 Mar 22.

Abstract

Background: Obesity is a common comorbid condition in adult asthmatics and known as a feature of asthma severity. However, the molecular mechanism under obesity-induced inflammation has not yet been fully understood.

Objective: Considering the essential role of hydrophobic surfactant protein B (SP-B) in lung function, SP-B was targeted to examine its involvement in the development of obesity-induced airway inflammation in asthmatics.

Methods: The aim was to examine an alteration in circulating SP-B according to obesity in adult asthmatics, 129 asthmatics were enrolled and classified into 3 groups (obese, overweight and normal-weight groups) according to body mass index (BMI). Circulating SP-B levels were determined by enzyme-linked immunosorbent assay. Four single nucleotide polymorphisms of SFTPB gene were genotyped. Serum ceramide levels were measured by liquid chromatography-tandem mass spectrometry.

Results: Significantly lower serum SP-B levels were noted in the obese group than in the overweight or normal-weight group (p = .002). The serum SP-B level was significantly correlated with serum levels of C18:0 ceramide and transforming growth factor beta 1 as well as BMI (r = -0.200; r = -0.215; r = -0.332, p < .050 for all). An inverse correlation was noted between serum SP-B and fractional exhaled nitric oxide levels in female asthmatics (r = -0.287, p = .009). Genetic predisposition of the SFTPB gene at 9306 A>G to the obese and overweight groups was noted.

Conclusion: Obesity altered ceramide metabolism leading to pulmonary surfactant dysfunction and impaired resolution of airway inflammation, finally contributing to the phenotypes of obese asthmatics.

Keywords: asthma; ceramide; obesity; surfactant protein B, airway, inflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Asthma* / diagnosis
  • Asthma* / genetics
  • Ceramides
  • Female
  • Humans
  • Inflammation
  • Obesity / complications
  • Overweight*
  • Surface-Active Agents
  • Transforming Growth Factor beta

Substances

  • IgA receptor
  • Ceramides
  • Transforming Growth Factor beta
  • Surface-Active Agents